clinical trial · NCT05593185

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

$SLS →·—·available

Acute Myeloid LeukemiaMyelodysplastic SyndromesGalinpepimut-S

brief summary

Single patient expanded access program to provide galinpepimut-S for eligible patients with AML or MDS who have no other treatment option.

started

—

primary completion

—

completion

—

last updated

Apr 24, 2026

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol